Despite the therapeutic efficacy of allogeneic bone marrow transplantation (allo-BMT), circulating hematopoietic progenitor cells after bone marrow transplantation have not been well characterized. In the present study, we focused on these 'post-transplant circulating progenitor cells (PTCPC)' which may be on their way to bone marrow. We analyzed the number of myeloid progenitor cells (CFU-GM) per 10 ml of peripheral blood (PB) on days 0 (just before transplantation), 1 (8-15 h after the completion of transplantation), 2, 3, 5, 7, 10, 14, 17, 21, 28 and 35 after allo-BMT in five transplant patients using a standard methylcellulose assay. In addition, high proliferative potential colony-forming cells (HPP-CFC) of the harvested donor bone marrow (BM) and day 1 PB of recipients were assayed in five patients. The origin of HPP-CFC from day 1 PB was analyzed by polymerase chain reaction of a DNA region containing a variable number of tandem repeats. The replating potential of these HPP-CFC was evaluated by a secondary colony assay. The proportion of CD38 negative cells among CD34 ؉ cells in the harvested BM and day 1 PB was evaluated by two-color flow cytometric analysis. The number of CFU-GM on day 1 ranged from 6 to 73/10 ml PB, and became undetectable on day 5. The reappearance of PTCPC was observed on day 14, along with hematopoietic recovery. The proportion of HPP-CFC among myeloid colonies from day 1 PB was significantly higher than that from harvested BM (44.3 ؎ 10.4% vs 11.3 ؎ 2.1%, respectively, n = 5, P = 0.0030). These HPP-CFC from day 1 PB were confirmed to be of donor origin. More than 90% of these HPP-CFC had replating potential. Two-color flow cytometric analysis revealed that the proportion of CD34 ؉ CD38 negative cells was significantly higher in day 1 PB than in the harvested BM (61.0 ؎ 16.5% vs 9.3 ؎ 3.5%, respectively, n = 7, P = 0.0002). These observations suggest that both primitive and committed transplanted myeloid progeniCorrespondence: Dr Y Katayama, Kobe West City Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, Hyogo 653-0013, Japan Received 17 August 1998; accepted 19 October 1998 tor cells may circulate in the very early period following allo-BMT.
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Summary:
Despite the therapeutic efficacy of allogeneic bone marrow transplantation (allo-BMT), circulating hematopoietic progenitor cells after bone marrow transplantation have not been well characterized. In the present study, we focused on these 'post-transplant circulating progenitor cells (PTCPC)' which may be on their way to bone marrow. We analyzed the number of myeloid progenitor cells (CFU-GM) per 10 ml of peripheral blood (PB) on days 0 (just before transplantation), 1 (8-15 h after the completion of transplantation), 2, 3, 5, 7, 10, 14, 17, 21, 28 and 35 after allo-BMT in five transplant patients using a standard methylcellulose assay. In addition, high proliferative potential colony-forming cells (HPP-CFC) of the harvested donor bone marrow (BM) and day 1 PB of recipients were assayed in five patients. The origin of HPP-CFC from day 1 PB was analyzed by polymerase chain reaction of a DNA region containing a variable number of tandem repeats. The replating potential of these HPP-CFC was evaluated by a secondary colony assay. The proportion of CD38 negative cells among CD34 ؉ cells in the harvested BM and day 1 PB was evaluated by two-color flow cytometric analysis. The number of CFU-GM on day 1 ranged from 6 to 73/10 ml PB, and became undetectable on day 5. The reappearance of PTCPC was observed on day 14, along with hematopoietic recovery. The proportion of HPP-CFC among myeloid colonies from day 1 PB was significantly higher than that from harvested BM (44.3 ؎ 10.4% vs 11.3 ؎ 2.1%, respectively, n = 5, P = 0.0030). These HPP-CFC from day 1 PB were confirmed to be of donor origin. More than 90% of these HPP-CFC had replating potential. Two-color flow cytometric analysis revealed that the proportion of CD34 ؉ CD38 negative cells was significantly higher in day 1 PB than in the harvested BM (61.0 ؎ 16.5% vs 9.3 ؎ 3.5%, respectively, n = 7, P = 0.0002). These observations suggest that both primitive and committed transplanted myeloid progeni- [3] [4] [5] described specific homing receptors and cytokine involvement 6 by which the homing process might be regulated. Papayannopoulou et al [7] [8] [9] showed that the VLA-4/VCAM-1 adhesion pathway plays a significant role in the homing process. However, these findings were made in mice or in non-human primates. Nothing has been elucidated about the homing phenomenon in humans.
Circulating hematopoietic progenitor cells after bone marrow transplantation, which may be on their way to bone marrow, have not been well characterized. In this study, we investigated the characteristics and kinetics of these posttransplant circulating progenitor cells (PTCPC), and found that hematopoietic progenitor cells circulate for a few days, and that primitive (CD34 ϩ CD38
dull-negative ) cells had a greater tendency to remain in the circulation than committed (CD34 ϩ CD38 ϩ ) cells 1 day after transplantation.
Materials and methods

Patients
Five allogeneic marrow transplant patients were used for the kinetic study of PTCPC, and their clinical characteristics are summarized in Table 1 . All patients received pretransplant conditioning therapy, including total body irradiation. Three were transplanted from HLA-identical sibling donors, and the remaining two from HLA-matched unrelated donors facilitated by the Japan Marrow Donor Program (JMDP). Cyclosporin A and methotrexate were given for GVHD prophylaxis. G-CSF (350 g/body/day) 660 was given from day 3 until neutrophil recovery. Engraftment was confirmed in all patients, and their posttransplant clinical courses were uneventful, without recurrence of disease for at least 4 months after allo-BMT. For the assay of high proliferative-potential colony forming cells (HPP-CFC), harvested bone marrow (BM) from donors and peripheral blood (PB) from recipients on day 1 after transplantation in five cases of allo-BMT were used.
All samples were obtained after informed consent.
Cell preparation
For the kinetic study of PTCPC, PB samples (10 ml) on the day of conditioning therapy and days 0 (just before transplantation), 1 (8-15 h after infusion), 2, 3, 5, 7, 10, 14, 17, 21, 28 and 35 were obtained with a heparinized syringe and diluted five-fold with phosphate-buffered saline (PBS). PB mononuclear cells (PBMNC) were separated by Ficoll-Hypaque (1.077 g/ml) density gradient centrifugation and washed twice with PBS. Bone marrow mononuclear cells (BMMNC) were prepared for progenitor assays in the same way.
Progenitor assay
All PBMNC thus obtained were used for progenitor assays without cell concentration adjustment on days 0, 1, 2, 3, 5, 7, 10 and/or 14 because only a small number of cells was obtained. On other days, the cell concentration was adjusted to 3-5 ϫ 10 5 cells/ml. For assays of burst-forming units erythroid (BFU-E) and colony-forming units granulocytemacrophage (CFU-GM), PBMNC were plated in 1 ml of the ready-made culture medium (Methocult GFH4434V, Stem Cell Technologies, Vancouver, Canada) in triplicate in 35 mm plastic culture dishes (Nunc, Roskilde, Denmark). This culture medium consisted of Iscove's modified Dulbecco's medium (IMDM), 0.88% methylcellulose, 30% fetal bovine serum (FBS), 1% bovine serum albumin, 2 mm l-glutamine, 1 ϫ 10 Ϫ4 m 2-mercaptoethanol, 3 U/ml recombinant human (rh) erythropoietin (Epo), 50 ng/ml rh stem cell factor (SCF), 10 ng/ml rh granulocyte-macrophage colony-stimulating factor (GM-CSF), 10 ng/ml rh interleukin-3 (IL-3), 10 ng/ml rh granulocyte colony-stimulating factor (G-CSF). The dishes were maintained at 37°C in a humidified atmosphere with 5% CO 2 , in air. After 21 days of culture, colonies of 40 or more cells were counted under an inverted microscope.
BMMNC were cultured in the same system at a cell concentration of 0.5-1 ϫ 10 5 cells/ml for the evaluation of BFU-E and CFU-GM, and maintained for 28 days in order to count HPP-CFC. HPP-CFC from day 1 PB were assayed similarly without cell concentration adjustment. HPP-CFC were counted (with a modification in diameter (Ͼ1.0 mm)) as described elsewhere.
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Cytokines
All cytokines used for replating assays (rhEpo, rhSCF, rhGM-CSF, rhIL-3, rhIL-6, rhG-CSF) were kindly provided by Kirin Brewery (Tokyo, Japan).
Secondary colony assay (replating assay)
Each of 25 HPP-CFC derived from 21-day cultures of day 1 PB from three patients was picked up by a micropipette and transferred into a well of 96-well plate (Costar, Cambridge, MA, USA) containing 0.1 ml IMDM with 10% FBS (Stem Cell Technologies) and mixed as described elsewhere. [12] [13] [14] The cells from each well were dispersed into a well of a 24-well plate (Nunc) for assaying their replating capacity in the secondary culture containing 0.5 ml of 0.88% IMDM-based methycellulose, 30% FBS (Stem Cell Technologies), 1% BSA (Fraction V; Sigma, St Louis, MO, USA), 2 mm l-glutamine, 5 ϫ 10 Ϫ5 m 2-ME (Sigma), 3 U/ml rhEpo, 50 ng/ml rhSCF, 10 ng/ml rhGM-CSF, 50 ng/ml rhIL-3, 10 ng/ml rhIL-6, 10 ng/ml rhG-CSF. After 21 days of incubation at 37°C with 5% CO 2 , secondary colonies were scored under an inverted microscope.
Polymerase chain reaction (PCR) of minisatellite region D1S80
Samples from three patients were studied. After 28 days of culture, individual HPP-CFC colonies from PB on days 1, 2 and 3, and on days 14, 17 and 21 during hematologic recovery after allo-BMT were removed from the dishes under an inverted microscope and then processed for PCR analysis. Colonies prior to conditioning and from harvested bone marrow were used as controls of recipient and donor, respectively. The host or donor origin of each colony was determined by amplification of the DIS80 loci containing a variable number of tandem repeats (VNTR) by PCR.
DNA extraction was performed as described elsewhere. 15 PCR was performed using a PCR amplification kit (AmpliFLP DIS80, PCR Amplification Kit; Perkin Elmer, Norwalk, CT, USA) according to the supplier's directions. Briefly, DNA was denatured for 4 min at 95°C, followed by 29 cycles of amplification performed at 95°C for 15 s, 66°C for 15 s and 72°C for 40 s. After the last cycle, the samples were held at 72°C for 10 min and were finally transferred to 4°C. Electrophoresis of the amplified DNA was carried out on 2% agarose gels. The amplification products were visualized directly with ethidium bromide.
Flow cytometric analysis
For the analysis of PTCPC in the very early post-transplant period, CD38 expression on CD34 ϩ cells from harvested donor BM and peripheral blood of recipients at 0 (immediately after the completion of infusion), 2, 5 and 12 h after transplantation were studied by two-color flow cytometric analysis in two cases of allo-BMT. The harvested BM and 10 ml of heparinized peripheral blood of recipients at each time-point were analyzed with a FACScan flow cytometer (Becton Dickinson (BD), San Jose, CA, USA) equipped with Cell Quest software (BD). After lysing red blood cells with lysing solution (BD), the cells were incubated with the binding buffer containing 1% normal mouse serum, on ice for 15 min, to prevent nonspecific binding. The cells were then incubated with fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated anti-CD34 (HPCA-2, BD) and anti-CD38 (Leu-17, BD) monoclonal antibodies (MoAbs). FITC-or PE-conjugated isotype-matched MoAbs were used as negative controls. At least 3 ϫ 10 4 cells were acquired in acquisition mode on a FACScan with a gate on forward and side scattering to exclude most of the monomyeloid cells. 16 In one case, progenitor assays were performed on harvested BM and peripheral blood at 0, 2 and 12 h after transplantation, as described above.
Surface markers, such as CD38, HLA-DR, VLA-4 and VLA-5, on CD34 ϩ cells from the harvested donor BM and day 1 PB from recipients were analyzed in the same way. The FITC-or PE-conjugated MoAbs used were as follows: anti-HLA-DR (BD), anti-CD49d (VLA-4; Immunotech, Marseille, France), and anti-CD49e (VLA-5; Immunotech).
Statistical analysis
Data were analyzed statistically by the paired t-test. A P value Ͻ0.05 was considered to be statistically significant.
Results
Kinetics of PTCPC
Post-transplant kinetics of BFU-E and CFU-GM are shown in Figure 1 . Although both BFU-E and CFU-GM diminished rapidly to undetectable levels on day 0, these PTCPC rose abruptly on day 1. The numbers of BFU-E on day 1 ranged from 5 to 44 per 10 ml PB, and those of CFU-GM from 6 to 73 per 10 ml PB, depending on the patient. After these transient increases, the PTCPC again diminished rapidly and became undetectable on day 5. PTCPC then reappeared on day 14, along with neutrophil and platelet recovery. Figure 2 shows representative results of CD34/CD38 twocolor flow cytometric analysis of harvested BM of a donor and PB of a recipient at 0, 2, 5 and 12 h after transplantation. The main population of CD34 ϩ cells in the harvested BM was the CD38 ϩϩ one. This population decreased in the PB of the recipient immediately after transplantation, and the main population of CD34 ϩ cells which remained in PB 12 h after transplantation was the CD34 ϩ CD38
Analysis of PTCPC in the very early post-transplant period
dull-negative one. Similar results were obtained from another case. The circulating CFU-GM 0, 2 and 12 h after transplantation represented 0.96%, 1.12%, 0.19% of infused BM CFU-GM, respectively.
Based on these data from the analysis of PTCPC in the very early post-transplant period, we focused on day 1 ϩϩ . However, this population decreased in the PB of the recipient immediately after transplantation, and the main population of CD34 ϩ cells which remained in PB 12 h after transplantation was the CD34 ϩ CD38 dull-negative one. Similar results were obtained from another case.
PTCPC, which included CD34
ϩ CD38 dull-negative cells as the main population. Table 2 shows the results of HPP-CFC assays in harvested donor BM and day 1 recipient PB. The proportion of HPP-CFC among myeloid colonies from day 1 PB was significantly higher than that from the harvested BM (44.3 Ϯ 10.4% vs 11.3 Ϯ 2.1%, respectively, n = 5, P = 0.0030). The mean percentages of circulating total myeloid progenitors, HPP-CFC and non-HPP-CFC myeloid progenitors on day 1 in the infused BM were 0.66% (range: 0.16-2.08), 2.94% (range: 0.84-9.16) and 0.28% (range: 0.10-1.10), respectively.
Analysis of harvested donor BM and day 1 recipient PB HPP-CFC:
In contrast to the frequent presence of large myeloid colonies in day 1 PB, most erythroid colonies were very small in size.
The colonies from PB on recovery day (day 14 or 17) were small in size. The percentages of HPP-CFC among myeloid colonies from PB on day 14 or 17 were less than 10%. 
Secondary colony assay:
A secondary colony assay was performed to evaluate the replating potential. [12] [13] [14] Table 3 shows the results of replating assays of day 1 PB-derived HPP-CFC. Twenty-three of 25 HPP-CFC could produce secondary colonies. The secondary colonies included CFU-GM, CFU-macrophage (CFU-M) and CFU-granulocyte Table 3 Types and numbers of secondary colonies 1  1  1  2  1 5  3  2  4  2  1  5  6  1  2  7  3  3  8  4  9  7  10  1  2  3  11  4  3  12  2  1  13  3  14  8  4  6  3  1 5  4  16  4  17  2  18  6  1  19  2  20  2  21  1  22  2  2  23  2  2  24 4 3 25 Figure 3 Results of VNTR analysis. PCR products from DNA of each colony derived from day 1 PB HPP-CFC were analyzed by gel electrophoresis in 2% agarose gel and visualized with ethidium bromide. Lane 1 contains DNA size standards from X174 digested with HaeIII. Lane 2, donor control; lane 3, recipient control; lanes 4-11, DNA from individual HPP-CFC-derived colonies from day 1 PB, which shows identical bands to the donor control.
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(CFU-G) colonies. All the secondary colonies were smaller in size than the primary ones.
VNTR analysis of individual colonies:
HPP-CFC-derived colonies from PB on days 1, 2 and 3, and on days 14, 17 and 21 during hematologic recovery were analyzed. The number of analyzed colonies was up to 19 at each point. A representative result from day 1 is shown in Figure 3 . Lanes 4-11 correspond to DNA from individual colonies, which showed identical bands to the donor control. All of the analyzed colonies were found to be of donor origin. Figure 4 , the percentage of the CD38 negative population among CD34 ϩ cells was significantly higher in day 1 PB than in the harvested donor BM (61.0 Ϯ 16.5% vs 9.3 Ϯ 3.5%, n = 7, P = 0.0002). The percentage of the VLA-4 negative population among CD34 ϩ cells was also significantly higher in day 1 PB than in harvested BM (81.7 Ϯ 11.4% vs 53.8 Ϯ 8.4%, n = 5, P = 0.0018). The mean fluorescence intensity of VLA-4 expression on CD34 ϩ cells in day 1 PB and harvested BM were 31.0 Ϯ 14.5 and 51.4 Ϯ 13.0, respectively (n = 5, P = 0.0036). However, there was no significant difference in the percentages of HLA-DR negative or VLA-5 negative populations among CD34 ϩ cells between day 1 PB and harvested BM; the percentages of CD34 
Flow cytometric analysis: As shown in
Discussion
In this study, we investigated the kinetics of hematopoietic progenitor cells (HPC) circulating in PB during the early stages following allo-BMT. Our results clearly indicate that PTCPC can be detected on day 1, although they were not detectable on day 0, just before transplantation. It was also demonstrated that these PTCPC were of donor origin and were detectable until day 3 post-transplant. Furthermore, we found that the CD34 ϩ CD38 dull-negative population, including HPP-CFC with replating potential, tended to remain in the circulation in the very early post-transplant period compared with the CD34 ϩ CD38 ϩ population, although most CD34 ϩ cells disappeared from the circulation immediately after transplantation.
It has been reported that the transient increase of leukocytes on days 1-3 after allo-BMT is of recipient origin, 17 and the origin of PB leukocytes gradually changes from recipient origin to donor origin during the 4 days after BMT. 18, 19 Although there is no evidence for circulation/trafficking of recipient stem/progenitor cells during these time-points of our data collection, the origin of the colony-forming cells in PB has not been determined. Our results indicate that progenitors of recipient origin immediately disappear or lose their clonogenic capacity after the myeloablative conditioning therapy, and instead, primitive and committed progenitors of donor origin circulate after transplantation.
Interestingly, more than 40% of myeloid colonies from day 1 PB were derived from HPP-CFC. These colonies could form secondary colonies, suggesting that they might have self-renewing capacity or high proliferative potential. [12] [13] [14] It is well known that HPP-CFC constitute a part of the primitive progenitor cells, 10, 11 and CD34 ϩ CD38 negative cells frequently include such primitive progenitors. 16, [20] [21] [22] The percentage of HPP-CFC in myeloid colonies from day 1 PB was as high as 40%, while that in harvested BM was around 10%. Furthermore, a CD38 dullෂnegative population among CD34 ϩ cells could be detected 8-15 h after transplantation. Although a few CD34 ϩ CD38 Ϫ cells in day 1 PB may be offered by the remaining recipient cells, most of them are considered to be of donor origin because the number of colonies was 0 from day 1 PB. These findings suggest that there may be a difference between the trafficking speed of primitive myeloid progenitors and that of committed ones in the very early post-transplant period.
Osogoe et al 23 reported that transplanted BM elements were detectable mainly in the lung, spleen, and liver 30 min after infusion in a rabbit model. Other investigators have also shown that transplanted BM cells in an irradiated mouse model lodged in several organs, including BM, spleen, lung and liver, although their presence in all other organs except the BM and spleen was transient. [24] [25] [26] Our results show that most CD34 dull CD38 ϩ cells were hardly detectable in day 1 PB from allotransplant patients. Accordingly, it is suggested that most of these cells may be trapped in the above-mentioned organs. This is an unsubstantiated assumption, since progenitors in the circulation during the second or third day could have come from tissues other than the bone marrow and are possibly on their way to home in bone marrow. Their fate is unknown. The fact that progenitors are finally undetectable at day 5 might indicate that they either die or that they have found the bone marrow.
VLA-4 is recognized to be very important in the hematopoietic stem cell-microenvironment interaction. [27] [28] [29] Papayannopoulou et al 7, 8 described the mobilization of early progenitors to the periphery by administration of anti-VLA-4 antibodies in a primate model, and claimed the importance of a VLA-4/VCAM-1 adhesion pathway. In our study, the percentage of the VLA-4 negative population among CD34 ϩ cells was significantly higher in day 1 PB than that in harvested donor BM. The importance of VLA-4 for homing of transplanted hematopoietic progenitors to the BM microenvironment may also apply in humans.
There are some reports concerning cytokine-mediated regulation of hematopoietic cell adhesiveness. 6, [30] [31] [32] [33] In particular, Levesque et al 32 reported that IL-3, GM-CSF and c-kit ligand could increase human hematopoietic cell adhesiveness by activating VLA-4 and VLA-5 integrins. However, since this event was observed within 30 min after cytokine stimulation, it is unlikely that the homing and adhesiveness of PTCPC is regulated by these cytokines in vivo during 3-5 days post-transplant.
Although we tried to characterize primitive and committed progenitor cells circulating in the very early phase after allo-BMT, it is still unknown why primitive HPC remain in the circulation for a short period before disappearing from the circulation while committed HPC rapidly disappear from the circulation, lodging in the BM or being trapped in other organs. It remains to be studied whether adhesion molecules on HPP-CFC will change their expression after homing to the BM, and whether circulating HPP-CFC will lose their clonogenic capacity without lodging in the BM. Thus, further studies will be required to clarify the role and biological significance of PTCPC in relation to not only short-term but also long-term hematopoietic reconstitution after allo-BMT.
